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accine efﬁcacy against carriage (VEcol)
xperimental human pneumococcal
a  b  s  t  r  a  c  t
Background:  Pneumococcal  carriage  is a reservoir  for transmission  and  a precursor  to  pneumococcal
disease.  The  experimental  human  pneumococcal  carriage  model  provides  a useful  tool  to aid  vac-
cine licensure  through  the  measurement  of vaccine  efﬁcacy  against  carriage  (VEcol).  Documentation
of  the  genetic  stability  of the  experimental  human  pneumococcal  carriage  model  is important  to  fur-
ther  strengthen  conﬁdence  in  its  safety  and  conclusions,  enabling  it to further  facilitate  vaccine  licensure
through  providing  evidence  of  VEcol.
Methods:  229  isolates  were sequenced  from  10 volunteers  in  whom  experimental  human  pneumococcal
carriage  was  established,  sampled  over  a period  of  35 days.  Multiple  isolates  from  within  a single  volun-
teer  at  a single  time  provided  a deep  resolution  for  detecting  variation.  HiSeq  data  from  the  isolates  were
mapped  against  a PacBio  reference  of  the  inoculum  to call  variable  sites.arriage Results:  The  observed  variation  between  experimental  carriage  isolates  was  minimal  with  the  maximum
SNP  distance  between  any  isolate  and  the reference  being  3 SNPs.
Conclusion:  The  low-level  variation  described  provides  evidence  for the  stability  of  the experimental
human  pneumococcal  carriage  model  over  35  days,  which  can be reliably  and  conﬁdently  used  to measure
VEcol  and  aid  future  progression  of  pneumococcal  vaccination.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Pneumococcal conjugate vaccines (PCV) have been introduced
cross the globe since 2000 to combat pneumococcal disease. The
ndirect effect of pneumococcal vaccination, through reduction of
accine-type carriage, has been a key contributor to conjugate
accine cost effectiveness [1–3]. However, carriage, which is nec-
ssary for both person-to-person transmission and spread within
he body, is not part of the current pneumococcal vaccine licensure
rocess [4]. Therefore, the impact of vaccination on nasopharyn-
eal carriage is of growing interest and has been presented as a
accine implementation and licensing aid [5]. Experimental human
neumococcal carriage offers a model to measure vaccine efﬁcacy
gainst carriage (VEcol) in a small, controlled population where
arriage can be monitored weekly, either as presence/absence or
y density and duration [6]. The model involves inoculating the
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nasopharynx of healthy adult volunteers with a known quantity of
serotype 6B. Serotype 6B was  selected for the experimental human
pneumococcal carriage model as it was a PCV vaccine type, had an
odds ratio of <1 for assessing invasive disease potential and had pre-
viously been used to investigate the immunizing effect of a carriage
episode [7–10]. It is important to understand the genomic stability
of the pneumococcal inoculum to further assess the safety of the
experimental carriage model and consider any potential impact this
could have on measuring VEcol. To this end, 229 experimental car-
riage isolates recovered from multiple volunteers and time-points,
were sequenced to document the number of variable sites.
2. Methods
2.1. Recruitment and ethics
Healthy volunteers were enrolled with informed consent to an
Experimental Human Pneumococcal Carriage trial [7]. All partic-
ipants were non-smoking adults aged 18–60 who had no close
contact with at risk individuals, including young children and the
elderly. Ethical approval was  obtained from the National Health
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table  1
Number of isolates per volunteer and time-point.
Days since i noculation (SNPs observed )
Volunteer 2 7 14 21 28 35 Total
362/172 10 10 10 10 7 47
382/193 8 8 8 7 8 39
381/192 8 2 8 8 26
391/203 8 8 8 1 1 26
368/178 2 10 3 8 23
366/176 1 10* 10 21
364/174 10 10 20
380/191 8 8 16

































t*col lec ted on day 8
 Collected on day 8.
ervice Research Ethics Committee (11/NW/0592) and the study
as sponsored by the Royal Liverpool and Broadgreen University
ospitals Trust.
.2. Experimental carriage
Pneumococcal stock preparation, inoculation and nasal wash
ere done as previously described [7]. Nasal washes were per-
ormed one week prior to pneumococcal challenge to determine
atural carriage status. Twenty-four volunteers that were negative
or natural pneumococcal carriage were inoculated with a serotype
B strain, multi locus sequence type ST138, and nasal washes were
aken on days 2, 7, 14, 21, 28 and 35 post-inoculation [11]. Carriage
ositive volunteers n = 10 received amoxicillin 500 mg T.D.S. for 3
ays after day 28 in order to ensure 6B colonisation clearance. One
olunteer (368/178, Table 1) did not have antibiotics until after day
5.
In carriage positive volunteers, up to ten individual pneumo-
occal colonies (where available) were taken from a blood agar
late following overnight incubation, added to 1 ml  of Todd Hewitt
roth containing 0.5% yeast extract and incubated at 37 ◦C, 5% CO2
or 7 h. The broth was then centrifuged at 17,000 × g for 3 min
nd the pellet was resuspended in 200 l sterile PBS and 40 l of
0 mg/ml  of RNAse A (Qiagen) and stored at −20 ◦C until extrac-
ion. DNA was extracted from the isolates using a modiﬁcation
f the QIAamp DNA Mini Kit (Qiagen). Brieﬂy, the sample was
dded to 100 l of TE buffer containing 0.04 g/ml lysozyme and
5 U/ml mutanolysin (Sigma) and incubated for 1 h at 37 ◦C. Fol-
owing incubation, proteinase K was added and the sample was
ncubated for 30 min  at 56 ◦C. Next, Buffer AL was  added, the sample
as incubated at room temperature for 10 min  and then 260 l of
thanol was added. All subsequent steps were as outlined in the kit
rotocol..3. Sequencing
Sequencing was performed at the Wellcome Trust Sanger Insti-
ute, on the Illumina HiSeq2000 platform. The inoculum was 33 (2015) 3342–3345 3343
sequenced using the PacBio platform to provide a reference
genome. Pacbio sequencing of the inoculum provided 335,112
ﬁltered sub-reads. De novo assembly was  performed with the
Hierarchical Genome Assembly Process HGAP.2, using PacBio’s
smrtanalysis version 2.1. The assembly was  blasted against itself
and inspected in Artemis Comparison Tool (ACT), 3 small spurious
contigs covered elsewhere in the assembly were removed and the
reads mapped back against the new assembly to create a ﬁnal con-
sensus fasta sequence using the PacBio SMRT Portal version v2.2.0
build 133,335. The resultant assembly had 6 contigs with a N50 of
1.15 Mb  (accession CTRR01000001–CTRR01000006). Supplemen-
tary Table 1 includes the ENA accession numbers for the sequence
data.
Illumina reads were mapped to the PacBio assembly of the
inoculum to identify single nucleotide polymorphisms (SNPs) using
SMALT [12] with GATK indel realignment [13] and ﬁltered with a
minimum base call quality of 50 and minimum mapping quality of
30 as previously described [14]. The SNP calling was replicated with
reduced minimum base call quality of 30 and minimum mapping
quality of 20. This was  to assess the potential numbers of false nega-
tives and indicate whether variation was  missed used the stringent
SNP calling, both approaches gave identical results. SNP alignments
were used to construct a maximum likelihood phylogenetic tree
with 100 bootstrap replicates of RAxML v7.0.4 [15] and combined
with temporal data to detect root to tip divergence in Path-O-Gen
[16].
3. Results
Of the 24 challenged volunteers, 10 were carriage positive for
serotype 6B ST138. From these 10 volunteers, 229 isolates from
multiple time-points were sequenced (Table 1).
3.1. Sequence variation
A total of 37 positions in the reference sequence contained a
SNP in at least one isolate (variable sites) and 232 SNPs were iden-
tiﬁed within the 229 isolates. No SNPs were detected for 59/229
isolates. The greatest number of SNP differences from the refer-
ence sequence for a single isolate was 3 (n = 8/229). No more than
11 variable sites were observed for all isolates taken from a sin-
gle volunteer. Seven or less variable sites were observed within
any volunteers time-point. Between 1 and 3 variable sites could
be observed at the primary time-point of 2 days for all volunteers
with the exception of 376/186. For 376/186 only two  isolates iden-
tical to the reference could be retrieved at day 2 and no isolates at
later time-points. Furthermore the variation observed within the
most comprehensive set of isolates from volunteer 362/172 was
only detected on day 2. All remaining 362/172 isolates (n = 37) were
identical to the reference sequence.
One shared SNP was  detected in multiple isolates from two
separate volunteers 380/191 (16/16 isolates) and 384/196 (4/9
isolates). The gene annotation for this SNP site in the reference
was DNA replication initiation control protein YabA. The C to A
transversion resulted in a non-synonymous change from Threonine
to Asparagine.
Horizontal exchange of genetic material (homologous recom-
bination), introducing multiple SNPs within a localised area of the
genome was not detected in this dataset with an average distance
of 55,694 base pairs (bp) and a minimum of 1319 bp between SNPs.
Full SNP proﬁles can be found in Supplementary Table 1.
The correlation between sampling time and different genetic
distances from the root to the tips of the phylogenetic tree was
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rend for increasing diversity over time was observed for the whole
ataset (n = 229) or for each volunteer’s isolates (data not shown).
. Discussion
Mutation and recombination contribute independently to evo-
ution of the pneumococcal genome. The mutation rate has been
reviously reported to equate to ∼3.14 SNPs per pneumococcal
enome (2 megabases) each year or 0.26 per month, for the Pneu-
ococcal Molecular Epidemiology Network clone 1 (PMEN1) and
as been found to be consistent across the species [17,18]. This has
ubsequently been reported to be representative of a number of
neumococcal lineages that include serotype 6B [17]. However, an
stimated 88% of SNPs in the PMEN1 lineage were due to recom-
ination events [18]. Micro and macro recombination events have
ach been estimated to only occur once every 17 years [19], rare
vents outside the timescale of experimental human pneumococcal
arriage. In addition multiple serotype colonisation, which could
rovide the opportunity for pneumococcal recombination events
as not detected in the volunteers. It is therefore not unexpected
hat recombination events were not detected in this study.
A report of the number of SNPs observed between seven inde-
endent natural pneumococcal carriage isolates sharing an ST that
lso belonged to serogroup 6 (6C) was previously observed to range
rom 67 through to 128 SNPs [20]. This is considerably more varia-
ion than that observed in this experimental carriage, especially
onsidering the smaller sample size and aggressive ﬁltering of
NPs in the 6C study. Two isolates from the 6C study that were
ollected from siblings and likely represent a transmission event
ere separated by only 8 SNPs. This is more comparable to the
umber of variable sites seen between individuals in experimen-
al carriage but multiple sampling from an individual may  have
evealed further within host diversity. Calculated mutation rates
re a description of the number of changes that occur and go to ﬁx-
tion and remain in the population, but many more mutations may
ccur that could be observed by deep sampling within a host that
o not become ﬁxed. One study of within host diversity for nat-
ral Staphylococcus aureus carriage reported between six and 40
NPs between isolates from a host at a single time-point [21]. Low-
evel sequence variation within the host for pneumococcal carriage
ould likely also be a common observation if deep sampling of
osts was performed routinely.
. Limitations
Whilst the number of volunteers closely followed was  small, the
epth of multiple isolate sequencing provided an insight into the
ariation within a volunteer at a single time-point and over time.
owever, we were not able to retrieve equal numbers of pneumo-
occal colonies from all individuals, which may  have been a factor of
acterial load, and therefore may  have missed further within host
ariation. It was important to look at isolate sequence variation in
ultiple hosts to assess any potential differences between hosts
ut this is limited by the isolates available for some volunteers.
The low level sequence variation observed, the presence of vari-
nts at the time-point 2 days after inoculation, and the observation
f a shared variable site in isolates from two volunteers could repre-
ent low-level un-sampled diversity contained within the original
noculum. The variation observed at the 2-day time-point for volun-
eer 362/172 could not be observed in all later time-points and may
ven represent the diversity stabilising over time or a bottleneck of
he carriage state.
The timescale of this study is short however to examine the
mpact of a vaccine on carriage acquisition, carriage only needs to
e detected once, right after challenge. 33 (2015) 3342–3345
6. Conclusion
In this sequencing study of serial isolates collected from an
experimental human pneumococcal carriage model we found low
rates of sequence variation between the isolates retrieved and the
original inoculum. Recombination events were not detected and
there was  no indication for evolution within the host with no
observed increasing diversity over time.
Carriage data could be used to measure the long-term impact
of vaccination and estimate post-vaccine changes in invasive dis-
ease incidence [22]. Because carriage is relatively easy to measure
and is more common than disease, it would require a much smaller
sample size in a vaccine trial, making it a very useful endpoint. The
low-level sequence variation observed within experimental car-
riage over 35 days provides a stable model that can be reliably used
to aid future progression of pneumococcal vaccination.
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